Table 1. The key targets of various agents in non-small-cell lung cancer in clinical phases of development.
Target proteins/receptors | Agents approved/under investigation for NSCLCs |
---|---|
EGFRs | Lapatinib†, afatinib (BIBW2992)†, dacomitinib (PF00299804), CO-1686, AZD9291, pertuzumab |
mTOR | Sirolimus, everolimus, temsirolimus |
BRAF | Dabrafenib (GSK2118436), vemurafenib (PLX4032), LGX818 |
MAPK | Trametenib (GSK1120212), selumetinib (AZD6244), GDC-0973 |
c-MET | EMD1214063, INC280, cabozantinib (XL184), tivantinib (ARQ197), foretinib (GSK1363089), onartuzumab (OAM4558g) |
FGFR/VEGFR | Cediranib, nintedanib (BIBF 1120), pazopanib†, ponatinib† [14] |
DDR2/Bcr-Abl | Dasatinib, sorafenib, ponatinib |
PIK3CA | PF-4989216 |
AKT | MK2206, GDC0068, AZD5363 |
ALK | Crizotinib (PF-02341066), LDK378, AP26113, CH5424802 |
RET | XL-184, sorafenib |
US FDA-approved drugs; for more information see [15].
EGFR: EGF receptor; FGFR: FGF receptor; NSCLC: Non-small-cell lung cancer; VEGFR: VEGF receptor.